Special Bulletin

Dec 21, 2020
The AHA today filed a motion asking the United States Court of Appeals for the D.C. Circuit to stay the price transparency rule until the new administration has the opportunity to review and revise it and because implementing it would divert essential personnel from caring for a huge influx of…
Dec 16, 2020
Special Bulletin The Food and Drug Administration (FDA) last week granted an emergency use authorization (EUA) to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine. As you are aware, distribution and administration of the first shipments are well underway across the country.
Dec 16, 2020
The Department of Health and Human Services (HHS) today announced that it has begun distributing $24.5 billion in “Phase 3” funds from the Public Health and Social Services Emergency Fund to eligible hospitals, as well as other providers. This amount is an increase from the $20 billion the…
Dec 15, 2020
A bipartisan group of senators and representatives yesterday released legislative text for both the Emergency Coronavirus Relief Act of 2020, a $748 billion COVID-19 relief package that boosts funding for health care providers, vaccines and testing, and the Bipartisan State and Local Support and…
Dec 14, 2020
To help hospitals and health systems understand what the federal appellate court’s “prudent layperson” standard decision means to them, AHA enlisted law firm Lash & Goldberg LLP to provide an in-depth analysis of the decision and its impact.
Dec 14, 2020
In-Depth Analysis of the “Prudent Layperson” Standard Decision’s Impact UPDATED WITH LINK Analysis of Court Decision on Legality of Health Plan ED Review Policies
Dec 12, 2020
Last night, House and Senate Committee leaders announced a bipartisan agreement to address surprise medical bills, the “No Surprises Act.” The bill is supported by House Ways and Means Committee Chairman Richard E. Neal (D-MA) and Ranking Member Kevin Brady (R-TX), House Energy and Commerce…
Dec 12, 2020
The Food and Drug Administration late last night granted an emergency use authorization (EUA) to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine, paving the way for its immediate administration across the country. Health care workers and nursing home residents will receive first priority and…